IGC PHARMA INC (IGC) Fundamental Analysis & Valuation

NYSEARCA:IGC • US45408X3089

0.2831 USD
-0.01 (-2.58%)
At close: Mar 12, 2026
0.2888 USD
+0.01 (+2.01%)
After Hours: 3/12/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IGC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

IGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IGC have multiple concerns. IGC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. IGC Profitability Analysis

1.1 Basic Checks

  • IGC had negative earnings in the past year.
  • In the past year IGC has reported a negative cash flow from operations.
  • In the past 5 years IGC always reported negative net income.
  • In the past 5 years IGC always reported negative operating cash flow.
IGC Yearly Net Income VS EBIT VS OCF VS FCFIGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • IGC's Return On Assets of -66.16% is on the low side compared to the rest of the industry. IGC is outperformed by 70.47% of its industry peers.
  • IGC's Return On Equity of -79.66% is on the low side compared to the rest of the industry. IGC is outperformed by 60.10% of its industry peers.
Industry RankSector Rank
ROA -66.16%
ROE -79.66%
ROIC N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
IGC Yearly ROA, ROE, ROICIGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Gross Margin of IGC (46.20%) is better than 64.77% of its industry peers.
  • IGC's Gross Margin has improved in the last couple of years.
  • IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
IGC Yearly Profit, Operating, Gross MarginsIGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. IGC Health Analysis

2.1 Basic Checks

  • IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IGC has more shares outstanding than it did 1 year ago.
  • IGC has more shares outstanding than it did 5 years ago.
  • IGC has a worse debt/assets ratio than last year.
IGC Yearly Shares OutstandingIGC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IGC Yearly Total Debt VS Total AssetsIGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -10.29, we must say that IGC is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -10.29, IGC is doing worse than 70.47% of the companies in the same industry.
  • IGC has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • IGC has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -10.29
ROIC/WACCN/A
WACC9.43%
IGC Yearly LT Debt VS Equity VS FCFIGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 1.32 indicates that IGC should not have too much problems paying its short term obligations.
  • The Current ratio of IGC (1.32) is worse than 74.09% of its industry peers.
  • IGC has a Quick Ratio of 1.32. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of IGC (0.89) is worse than 77.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.89
IGC Yearly Current Assets VS Current LiabilitesIGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IGC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.49% over the past year.
  • IGC shows a decrease in Revenue. In the last year, the revenue decreased by -6.51%.
  • IGC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.77% yearly.
EPS 1Y (TTM)58.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.06%
Revenue 1Y (TTM)-6.51%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%-53.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.20% on average over the next years. This is quite good.
  • Based on estimates for the next years, IGC will show a quite strong growth in Revenue. The Revenue will grow by 9.74% on average per year.
EPS Next Y12.09%
EPS Next 2Y10.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.61%
Revenue Next 2Y9.74%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IGC Yearly Revenue VS EstimatesIGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
IGC Yearly EPS VS EstimatesIGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2

More info and screens

Find the best growth stocksShow best growing peers

0

4. IGC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IGC. In the last year negative earnings were reported.
  • Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGC Price Earnings VS Forward Price EarningsIGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGC Per share dataIGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.2%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IGC Dividend Analysis

5.1 Amount

  • No dividends for IGC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IGC Fundamentals: All Metrics, Ratios and Statistics

IGC PHARMA INC

NYSEARCA:IGC (3/12/2026, 8:04:00 PM)

After market: 0.2888 +0.01 (+2.01%)

0.2831

-0.01 (-2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)06-25
Inst Owners19.49%
Inst Owner ChangeN/A
Ins Owners3.8%
Ins Owner Change-0.22%
Market Cap27.13M
Revenue(TTM)1.11M
Net Income(TTM)-6.45M
Analysts80
Price Target3.7 (1206.96%)
Short Float %0.66%
Short Ratio1.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-21.1%
Min Revenue beat(2)-41.81%
Max Revenue beat(2)-0.38%
Revenue beat(4)2
Avg Revenue beat(4)-8.52%
Min Revenue beat(4)-41.81%
Max Revenue beat(4)7.13%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-36.38%
EPS NQ rev (3m)-36.38%
EPS NY rev (1m)-25.9%
EPS NY rev (3m)-25.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.53
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB 8.44
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.01
BVpS0.08
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.16%
ROE -79.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.2%
FCFM N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.74%
Cap/Sales 64.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.89
Altman-Z -10.29
F-Score2
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)84.26%
Cap/Depr(5y)139.57%
Cap/Sales(3y)48.11%
Cap/Sales(5y)101.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.06%
EPS Next Y12.09%
EPS Next 2Y10.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.51%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%-53.64%
Revenue Next Year4.61%
Revenue Next 2Y9.74%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.44%
OCF growth 3YN/A
OCF growth 5YN/A

IGC PHARMA INC / IGC FAQ

What is the fundamental rating for IGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to IGC.


What is the valuation status of IGC PHARMA INC (IGC) stock?

ChartMill assigns a valuation rating of 0 / 10 to IGC PHARMA INC (IGC). This can be considered as Overvalued.


How profitable is IGC PHARMA INC (IGC) stock?

IGC PHARMA INC (IGC) has a profitability rating of 1 / 10.


Can you provide the financial health for IGC stock?

The financial health rating of IGC PHARMA INC (IGC) is 1 / 10.